Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

(2012) Hidehiro Itonaga et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

(2011) A. Fabarius et al.   BLOOD

Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFN  via accelerating the degradation of its receptor

(2011) S. Bhattacharya et al.   BLOOD

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

(2011) J. Hasford et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

(2011) E. Jabbour et al.   BLOOD

Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation

(2011) A. Megan Cornelison et al.   Clinical Lymphoma Myeloma & Leukemia

Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia

(2011) Izhar Hardan et al.   CYTOKINE

Clinical reagents of GM-CSF and IFN-α induce the generation of functional chronic myeloid leukemia dendritic cells in vitro

(2011) Kaizhi Weng et al.   CYTOTECHNOLOGY

Current status of agents active against the T315I chronic myeloid leukemia phenotype

(2011) Aine Carol Burke et al.   EXPERT OPINION ON EMERGING DRUGS

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

(2011) N. Takahashi et al.   HAEMATOLOGICA

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

(2011) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

(2010) Jorge Cortes et al.   CANCER

The response to imatinib and interferon-  is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

(2010) F. Palandri et al.   HAEMATOLOGICA

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia

(2010) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal

(2010) Shreya Kanodia et al.   PLoS One

High rates of durable response are achieved with imatinib after treatment with interferon   plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

(2009) F. Guilhot et al.   HAEMATOLOGICA

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Harmonization of molecular monitoring of CML therapy in Europe

(2009) M C Müller et al.   LEUKEMIA

IFNα activates dormant haematopoietic stem cells in vivo

(2009) Marieke A. G. Essers et al.   NATURE

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome

(2008) F. Palandri et al.   HAEMATOLOGICA

Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate

(2007) Giuliana Alimena et al.   LEUKEMIA RESEARCH